

**Subject:** Listening Session for Substance Use Disorders: Availability of Benefits

**Message:** The Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities Act ([SUPPORT Act](#)) outlines national strategies to help address opioid misuse. Section 6084 of *Studying the Availability of Supplemental Benefits Designed to Treat or Prevent Substance Use Disorders under Medicare Advantage Plans*, requires CMS to evaluate the extent to which Medicare Advantage plans offer supplemental benefits to treat or prevent substance use disorders (SUDs) not otherwise covered under traditional Medicare including how Medicare Advantage plans make the determination to offer supplemental benefits to treat SUDs.

On Wednesday, February 26, 2020 from 2:00 to 3:30 pm ET, CMS is holding a listening session to solicit feedback from Medicare Advantage Organizations and Pharmacy Benefit Managers on this critical topic. CMS is specifically interested in learning from stakeholders regarding the:

- Availability of supplemental benefits to treat or prevent SUDs;
- Challenges associated with offering SUD-related supplemental benefits; and
- Solutions to improve coverage and/or availability of SUD-related supplemental benefits to improve care.

Please use this link [SUD Listening Session](#) to register for this listening session.